12 Month Price Forecast For KMDA
Distance to KMDA Price Forecasts
KMDA Price Momentum
๐ค Considering Kamada (KMDA)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 8, 2025 3:55 AM UTC
KMDA Analyst Ratings & Price Targets
Based on our analysis of 3 Wall Street analysts, KMDA has a consensus that is bullish. The median price target is $13.00, with forecasts ranging from $11.00 to $20.00. Currently, there are 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With KMDA currently trading at $7.69, the median price forecast suggests a 69.1% upside. The most optimistic forecast comes from at , projecting a 160.1% upside, while Andrew Fein at HC Wainwright & Co. provides the most conservative target, suggesting a 43.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KMDA Analyst Consensus
KMDA Price Target Range
Latest KMDA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KMDA.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 10, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
Nov 14, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
Aug 15, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
Jul 3, 2024 | Stifel | Annabel Samimy | Buy | Initiates | $18.00 |
May 9, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
Mar 7, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
Nov 14, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
Aug 17, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
May 25, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
Mar 16, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $11.00 |
Feb 2, 2018 | Chardan Capital | Buy | Initiates | $7.00 | |
Nov 13, 2015 | Jefferies | Buy | Maintains | $8.00 | |
Jun 25, 2013 | Morgan Stanley | Equal-Weight | Initiates | $0.00 | |
Jun 25, 2013 | Oppenheimer | Outperform | Initiates | $0.00 | |
Jun 25, 2013 | Jefferies | Buy | Initiates | $0.00 |
Stocks Similar to Kamada Ltd
The following stocks are similar to Kamada based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Kamada Ltd (KMDA) Financial Data
Kamada Ltd has a market capitalization of $394.27M with a P/E ratio of 25.4x. The company generates $154.57M in trailing twelve-month revenue with a 9.8% profit margin.
Revenue growth is +13.4% quarter-over-quarter, while maintaining an operating margin of +13.3% and return on equity of +7.0%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Kamada Ltd (KMDA) Company Overview
About Kamada Ltd
Manufactures and sells plasma-derived protein therapeutics.
The company generates revenue through the production and sale of a wide range of plasma-derived protein therapeutics, as well as the distribution of imported drug products in Israel. Its commercial offerings cater to various medical needs, including prophylactic treatments for infectious diseases, immune system disorders, and chronic conditions.
Kamada Ltd. was established in 1990 and is based in Rehovot, Israel. The company has a diverse product portfolio, providing both proprietary and imported therapies, which positions it well within the biotechnology sector. Its ongoing commitment to innovation and expanding its therapeutic offerings highlights its potential for growth in the healthcare market.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
378
CEO
Country
Israel
IPO Year
2010
Website
www.kamada.comKamada Ltd (KMDA) Latest News & Analysis
Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRABยฎ and VARIZIGยฎ in Latin America
17 days agoKamada Ltd. secured a three-year contract for $25 million to supply KAMRABยฎ and VARIZIGยฎ in Latin America for 2025-2027, impacting its 2025 revenue guidance.
Kamada Ltd.'s $25 million contract for KAMRABยฎ and VARIZIGยฎ enhances revenue visibility and growth potential, positively impacting stock performance and investor confidence.
Kamada Ltd. (KMDA) Q3 2024 Earnings Call Transcript
2 months agoKamada Ltd. (NASDAQ:KMDA) will hold its Q3 2024 earnings conference call on November 13, 2024, at 08:30 AM ET, featuring key company executives.
Kamada Ltd.'s upcoming Q3 2024 earnings call may provide insights into financial performance and strategic direction, influencing market sentiment and stock valuation.
Kamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in Houston
4 months agoKamada Ltd. has opened a new 12,000 sq. ft. plasma collection center in Houston, TX, expanding its operations with over 50 donor beds and an annual capacity of 50,000 liters.
Kamada Ltd.'s new plasma collection center in Houston expands capacity, potentially increasing revenue and market presence in the biopharmaceutical sector, positively impacting stock performance.
Kamada Ltd. (KMDA) Q2 2024 Earnings Call Transcript
5 months agoKamada Ltd. (NASDAQ: KMDA) will hold its Q2 2024 Earnings Conference Call on August 14, 2024, at 8:30 AM ET, featuring key company executives and financial analysts.
Kamada Ltd.'s Q2 2024 earnings call indicates upcoming financial insights, potentially impacting stock performance and investor sentiment based on results and guidance.
Kamada Ltd. (NASDAQ: KMDA) will release its Q2 and first half financial results for 2024 on August 14, 2024, before U.S. market open.
Kamada Ltd.'s upcoming financial results release could impact stock performance, providing insights into revenue and growth in the biopharmaceutical sector, especially for plasma-derived products.
Biotech stocks priced under $10 are highlighted as potentially viable investment opportunities within the biotechnology industry.
Biotech stocks under $10 may offer high growth potential at lower entry costs, attracting investors seeking value in a sector known for innovation and volatility.
Frequently Asked Questions About KMDA Stock
What is Kamada Ltd's (KMDA) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Kamada Ltd (KMDA) has a median price target of $13.00. The highest price target is $20.00 and the lowest is $11.00.
Is KMDA stock a good investment in 2025?
According to current analyst ratings, KMDA has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.69. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for KMDA stock?
Wall Street analysts predict KMDA stock could reach $13.00 in the next 12 months. This represents a 69.1% increase from the current price of $7.69. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Kamada Ltd's business model?
The company generates revenue through the production and sale of a wide range of plasma-derived protein therapeutics, as well as the distribution of imported drug products in Israel. Its commercial offerings cater to various medical needs, including prophylactic treatments for infectious diseases, immune system disorders, and chronic conditions.
What is the highest forecasted price for KMDA Kamada Ltd?
The highest price target for KMDA is $20.00 from at , which represents a 160.1% increase from the current price of $7.69.
What is the lowest forecasted price for KMDA Kamada Ltd?
The lowest price target for KMDA is $11.00 from Andrew Fein at HC Wainwright & Co., which represents a 43.0% increase from the current price of $7.69.
What is the overall KMDA consensus from analysts for Kamada Ltd?
The overall analyst consensus for KMDA is bullish. Out of 3 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $13.00.
How accurate are KMDA stock price projections?
Stock price projections, including those for Kamada Ltd, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.